Drug Trial Radar · NCT04133909
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
806
Actual
Start
Oct 30, 2019
Primary completion
Aug 8, 2024
Study completion Aug 8, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- Oct 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 109 weeks, consisting of 2 screening visits (up to 3 weeks), a run-in period (up to 2 weeks), and an intervention period of at least 52 weeks and up to 104 weeks. 800 participants will be randomized in a 1:1 ratio to receive mepolizumab 100 milligrams (mg) or placebo every 4 weeks for at least 13 doses (52 weeks treatment period) up to a maximum of 26 doses (104 weeks treatment period). The number of randomized participants may increase up to approximately 1400.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
MepolizumabBiological
Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.
PlaceboDrug
Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate or Severe ExacerbationsTime frame: Up to Week 104
Locations
339 sites in 26 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Dothan, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Jasper, Alabama
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Gilbert, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Conway, Arkansas
GSK Investigational Site
Alpine, California
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Vista, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Daytona Beach, Florida
GSK Investigational Site
Doral, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Homestead, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pinellas Park, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Port Orange, Florida
GSK Investigational Site
St. Petersburg, Florida
Showing 40 of 339 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.